跳转至内容
Merck
所有图片(1)

文件

T2705

Sigma-Aldrich

拓扑替康 盐酸盐 水合物

≥98% (HPLC and enzymatic), powder, topoisomerase I inhibitor

别名:

9-[（二甲基氨基）甲基]-10-羟基-（20S）-喜树碱 盐酸盐 水合物, NSC-609669 盐酸盐 水合物, SKF-104864A 盐酸盐 水合物, 拓扑替康 盐酸盐 水合物

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C23H23N3O5 · xHCl · yH2O
CAS号:
123948-87-8
分子量:
421.45 (anhydrous free base basis)
MDL號碼:
MFCD00870670
分類程式碼代碼:
12352200
PubChem物質ID:
329826724
NACRES:
NA.77

product name

拓扑替康 盐酸盐 水合物, ≥98% (HPLC and enzymatic)

化驗

≥98% (HPLC and enzymatic)

形狀

powder

儲存條件

desiccated
protect from light

顏色

yellow

溶解度

DMSO: ≥20 mg/mL

起源

GlaxoSmithKline

儲存溫度

−20°C

InChI

1S/C23H23N3O5/c1-4-23(30)16-8-18-20-12(9-26(18)21(28)15(16)11-31-22(23)29)7-13-14(10-25(2)3)19(27)6-5-17(13)24-20/h5-8,27,30H,4,9-11H2,1-3H3/t23-/m0/s1

InChI 密鑰

UCFGDBYHRUNTLO-QHCPKHFHSA-N

基因資訊

human ... TOP1MT(116447)

應用

拓扑替康作为阳性对照，已被用作低氧条件下人神经胶质瘤细胞中HIF-1α 和VEGF抑制剂的鉴定和分析1。它也被用于 体外 PA317细胞的凋亡检测2。

生化／生理作用

拓扑替康是一种拓扑异构酶I抑制剂和凋亡诱导剂。它是一种有效的抗肿瘤药。

特點和優勢

该化合物由GlaxoSmithKline开发。要浏览其他药物开发化合物和批准的药物/候选药物列表，单击此处。
这种化合物是ADME毒性和凋亡研究的特色产品。发现更多有关ADME毒性 和 凋亡 的特色产品。在sigma.com/discover-bsm可了解更多关于生物活性小分子的其他研究领域。

準備報告

水合盐酸拓扑替康可溶于DMSO，溶解浓度大于等于20 mg/ml。

象形圖

Health hazard
GHS08

訊號詞

Danger

危險聲明

H340,H361d

危險分類

Muta. 1B - Repr. 2

儲存類別代碼

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

水污染物質分類（WGK）

WGK 3

閃點（°F）

Not applicable

閃點（°C）

Not applicable

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Ian F King et al.
Nature, 501(7465), 58-62 (2013-09-03)
Topoisomerases are expressed throughout the developing and adult brain and are mutated in some individuals with autism spectrum disorder (ASD). However, how topoisomerases are mechanistically connected to ASD is unknown. Here we find that topotecan, a topoisomerase 1 (TOP1) inhibitor
Jerec W Ricci et al.
Molecular cancer therapeutics, 15(12), 2853-2862 (2016-09-28)
Chemotherapeutic resistance remains a challenge in the treatment of ovarian carcinoma, especially in recurrent disease. Despite the fact that most patients with newly diagnosed tumors attain complete remission following cytoreductive surgery and chemotherapy, ovarian carcinoma has a recurrence rate that
Iben Kümler et al.
Breast cancer research and treatment, 138(2), 347-358 (2013-03-21)
Following treatment with anthracyclines and taxanes, few established options exist for the treatment of metastatic breast cancer (MBC). Although the topoisomerase 1 inhibitors irinotecan, etirinotecan, and topotecan have been used in clinical trials on MBC, the drugs have never been
Andrei Molotkov et al.
Pharmaceutics, 13(3) (2021-04-04)
Glioblastoma (GBM) is the most common primary adult brain malignancy with an extremely poor prognosis and a median survival of fewer than two years. A key reason for this high mortality is that the blood-brain barrier (BBB) significantly restricts systemically
Israel Zighelboim et al.
Gynecologic oncology, 130(1), 64-68 (2013-04-18)
We evaluated the activity and safety of the combination of topotecan, cisplatin and bevacizumab in patients with recurrent or persistent carcinoma of the cervix. Eligible patients had persistent or recurrent cervical cancer not amenable to curative intent treatment. No prior
查看所有相关文献

商品

Discover Bioactive Small Molecules for Cell Cycle

Cell cycle phases (G1, S, G2, M) regulate cell growth, DNA replication, and division in proliferating cells.

Bioactive Molecules for Apoptosis

Apoptosis regulation involves multiple pathways and molecules for cellular homeostasis.

Discover Bioactive Small Molecules for ADME/Tox

Discover Bioactive Small Molecules for ADME/Tox

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门